Vitamin K2 as MK-7 100 mcg by Futurebiotics — Ingredients, Evidence & Safety

🟢 100/100

This product looks safe

No ingredients exceed tolerable upper intake levels
100% of ingredients have research evidence

A Label Compliance Grade

Product Label

📄 Open Full PDF View on NIH DSLD →

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

1 Capsule(s) Serving Size

200 Servings

Vitamin Product Type

100% Evidence Coverage

Supplement Facts — Evidence Check

Vitamin K2

100 mcg (83% DV)

✅ Within RDA (0.8× RDA of 0.12 mg) 📚 273 studies (Tier A: 9, B: 175)

RDA 0.12mg This product: 0.1mg

Other Ingredients

Microcrystalline Cellulose Modified Cellulose Magnesium Stearate Silicon Dioxide

Label Claims — Verification

❓ Nutrient

❓ All Other

❓ Structure/Function

All Other (100% of products) Structure/Function (84% of products) Nutrient (73% of products)

Target Groups

Adult (18 - 50 Years) Women (not pregnant or lactating) Gluten Free

Product Information

📋 Directions for Use

Directions: As a dietary supplement for adults, take 1 capsule daily, preferably with a meal or as directed by a healthcare professional.

⚠️ Warnings & Precautions

Warning: Do not take this product if you are pregnant or nursing. Consult a physician before taking this product if you have a medical condition or are taking medication, especially anticoagulant, and antiplatelet medications, have a bleeding disorder, or planning a medical procedure.

Discontinue use and consult a healthcare professional in case of adverse reaction.

Do not use if seal under cap is broken or missing.

🧪 Formulation Notes

Vitamin K2 as MK-7 100mcg per capsule

Supports strong bones Healthy cardiovascular support

Free of gluten and soy Lab tested GMO free

Additional Information

Lab tested GMO free

Product Details

UPC / SKU 0 49479 85720 3

DSLD Entry Date 2024-11-22

Product Type Vitamin

Form Capsule

Brand Futurebiotics

DSLD ID 320010

Data Updated 2026-04-11

Research Evidence

332 Research Sources

59 Avg Quality Score

220 Meta Analysis

56 Systematic Review

30 Rct

16 Clinical Trial

3 Guideline

3 Regulatory Source

1 Narrative Review

1 Other

1 Openfda Safety

A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism

Meta Analysis The Cochrane database of systematic reviews 2014

PubMed DOI Cochrane

A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome

Meta Analysis The Cochrane database of systematic reviews 2017

PubMed DOI

A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Meta Analysis The Cochrane database of systematic reviews 2016

PubMed DOI

A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome

Meta Analysis The Cochrane database of systematic reviews 2020

PubMed DOI

A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair

Meta Analysis The Cochrane database of systematic reviews 2025

PubMed DOI

A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation

Meta Analysis The Cochrane database of systematic reviews 2018

PubMed DOI

A Antiplatelet agents and anticoagulants for hypertension

Systematic Review The Cochrane database of systematic reviews 2022

PubMed DOI

A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy

Meta Analysis The Cochrane database of systematic reviews 2012

PubMed DOI

A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation